Wells Fargo Cuts Sarepta PT to $38, Baird Lowers Target to $20
Wells Fargo cut Sarepta Therapeutics’ price target to $38 from $45, citing delays in GTx launch and revised ELEVIDYS forecasts, while Baird lowered its target to $20 from $22 after full-year 2025 net product revenues of $1.864 billion and Q4 sales of $369.6 million. Both analysts retained their ratings.
1. Wells Fargo Price Target Reduction
Wells Fargo lowered its price target for Sarepta Therapeutics to $38 from $45 following a review of the company’s 2026 guidance. The analyst cited extended timelines for the GTx launch reset post-safety events and adjusted ELEVIDYS forecasts, though it retained an Overweight rating and flagged a likely positive siRNA readout.
2. Baird’s Target Cut and Revenue Review
Baird cut its target on Sarepta shares to $20 from $22 after evaluating fiscal Q4 and full-year 2025 results. The firm reported net product revenues of $1.864 billion in 2025—$965.6 million from PMO and $898.7 million from ELEVIDYS—and Q4 revenues of $369.6 million, maintaining a Neutral rating.
3. Analyst Implications and Investor Outlook
These downward price target revisions reflect analyst concerns over launch delays and revenue trajectories, but both firms emphasize potential upside from upcoming siRNA data. Investors will monitor clinical readouts and product launches as key catalysts for future valuation shifts.